Cited in 2024 inMolecular Degeneration,PMID:38862989
and in 2020 inJournal of Parkinson's Disease,PMID:32007961
NeuroMab antibodies arerecognized by the industryas setting an early standard for a well-characterized antibody. With over 150 citations, our NeuroMab cloneN241A/34is beloved for its utility as a detection antibody in WB, IHC, and ICC.
Recent publications have expanded its scope:as a capture antibody in ELISA for both total LRRK2 (12.1 pg/mL) and phospho-LRRK2 ser935 (4 pg/mL)!
Yuan, et al. at Duke University found elevated LRRK2 kinase activity in the periphery (the ratio of pT73-Rab10 to total Rab10) to be a biomarker for exacerbated inflammation correlating with worsened disease endpoints in iPD. PMID:38862989
Padmanabhan, et al from the Michael J Fox Foundation found that a patient's pS935 LRRK2 level has the potential to be a disease state biomarker of G2019S LRRK2-associated PD. PMID:32007961
Immunoblot versus crude membranes from adult rat brain (RBM) and wild-type (WT) and LRRK2 KO mouse brains probed with N241A/34 (left) and K89/41 (right) TC supe. Mouse brain samples provided by Xiaojie Li, Ted Dawson and Valina Dawson (Johns Hopkins University).
Chemiluminescent immunoblot of endogenous LRRK2 (cat. 75-253) in cytoplasmic and membrane fractions of B16 melanocytes with Rab38 versus control siRNA knockdown. TFRC and GAPDH are used as membrane and cytoplasmic markers, respectively. Image from publication CC-BY-4.0. PMID:37625589
Just Released: Recombinant Chimeric Chicken Antibodies!
5 of our most popular NeuroMab cell marker targets are now available inrecombinant chimeric versions:
A chimeric antibody is genetically engineered to combine sequences from antibodies of two different species. Advantages includeeasy multiplexing, increasedreproducibility,lower background, andanimal-friendly production!
